Kenvue Strips Bond Covenants Ahead of Kimberly-Clark Merger Close
KVUE sits 28% above its 52-week low of $14.02.
Summary
Kenvue amended its bond indentures to remove restrictive covenants and reporting requirements, effective upon settlement of exchange offers tied to the Kimberly-Clark acquisition closing.
Key Events · M&A and Partnerships · KVUE
-
Third Supplemental Indenture Executed
On October 9, 2026, Kenvue entered into a Third Supplemental Indenture with Deutsche Bank Trust Company Americas, as trustee, amending the indenture governing its seven series of senior notes totaling $7.0 billion in aggregate principal.
-
Covenants and Defaults Eliminated
The amendments eliminate substantially all restrictive covenants, certain events of default (other than payment defaults), the SEC reporting covenant, and restrictions on mergers, consolidations, and asset transfers for each series of Existing Kenvue Notes.
-
Operative Upon Exchange Offer Settlement
The amendments become operative only upon settlement of the Exchange Offers and Consent Solicitations, expected to occur on or about the closing date of the Kimberly-Clark acquisition of Kenvue.
-
Exchange Offers Up to $7 Billion
Kimberly-Clark is offering to exchange any and all Existing Kenvue Notes for up to $7.0 billion aggregate principal amount of new Kimberly-Clark notes and cash, pursuant to a confidential offering memorandum dated September 28, 2026.
Analysis · KVUE · Life Sciences
Kenvue entered into a Third Supplemental Indenture that eliminates substantially all restrictive covenants, most events of default, the SEC reporting covenant, and merger restrictions on its $7 billion of outstanding senior notes. The amendments become operative only upon settlement of the exchange offers, which is expected to occur on or about the closing date of the Kimberly-Clark acquisition. This is a standard step in the merger financing process — Kimberly-Clark is offering to exchange Kenvue's existing notes for new Kimberly-Clark notes and cash, and the covenant stripping aligns the old notes with the post-merger capital structure. For bondholders, the loss of covenants reduces protections, but the exchange offer provides an exit. For equity holders, this confirms the merger is progressing toward close.
How filings like this one have moved
In the 30 days to Oct 29, 2026, 31.1% of the 1661 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, KVUE was trading at $17.96 on NYSE in the Life Sciences sector, with a market capitalization of approximately $34.2B. The 52-week trading range was $14.02 to $20.13. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.